

## *Supplementary Material for*

# **Clinical development and informatics analysis of natural and semi-synthetic flavonoid drugs: a critical review**

Kuo Xu <sup>a,c,†</sup>, Xia Ren <sup>a,c,†</sup>, Jintao Wang <sup>d</sup>, Qin Zhang <sup>d</sup>, Xianjun Fu <sup>a,c,\*</sup>, Pei-Cheng Zhang <sup>b,\*</sup>

<sup>a</sup> *Research Institute for Marine Traditional Chinese Medicine, Key Laboratory of Marine Traditional Chinese Medicine in Shandong Universities, Shandong Engineering and Technology Research Center on Omics of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250355, China*


<sup>b</sup> *State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100050, China*

<sup>c</sup> *Qingdao Academy of Chinese Medical Sciences Shandong University of Traditional Chinese Medicine, Qingdao Key Laboratory of Research in Marine Traditional Chinese Medicine, Qingdao Key Technology Innovation Center of Marine Traditional Chinese Medicine's Deep Development and Industrialization, Qingdao 266114, China*


<sup>d</sup> *Chongqing Kangzhou Big Data (Group) Co., Ltd. Chongqing 401336, China*

† These authors contributed equally to this work.


\*Corresponding authors. E-mail address: [fuxianjun@sdutcm.edu.cn](mailto:fuxianjun@sdutcm.edu.cn) (X.-J. Fu), [pczhang@imm.ac.cn](mailto:pczhang@imm.ac.cn) (P.-C. Zhang);




**Scheme S1.** The semi-synthetic routes and reference for flavonoid-derived drug molecules **3**, **7**, **8**, **10**, **11**, **14**, **16**, and **19**.



**Scheme S2.** The semi-synthetic routes and reference for flavonoid-derived drug candidates **22-25**, **33**, and **37-39**.



**Scheme S3.** The semi-synthetic routes and reference for flavonoid-derived drug candidates **40-44**, **46**, and **47**.




**Scheme S4.** The semi-synthetic routes and reference for flavonoid-derived drug candidates **48**, **49**, and **53-55**.

## References

- [1] Khanapur M, Pinna NK, Badiger J. Synthesis and anti-inflammatory *in vitro*, *in silico*, and *in vivo* studies of flavone analogues. *Medicinal chemistry research*, 2015, 24: 2656-2669.
- [2] Huang Y, Sun G, Wang P, et al. Synthesis and biological evaluation of Complex I inhibitor R419 and its derivatives as anticancer agents in HepG2 cells. *Bioorganic & Medicinal Chemistry Letters*, 2018, 28(17): 2957-2960.
- [3] Mesanguy, Maurice, Sodium flavone -5,7-dioxyacetate - from 5,7-dihydroxy flavone by acet formation and hydrolysis. France, FR2076753, 1971-11-19.

- [4] Huang XP, Huang YQ, Yang R, et al. Synthesis craft of troxerutin. *Journal of Henan Normal University (Natural Science Edition)*, 2011, 39(3): 89-91.
- [5] Pan XW, Peng L, Xia T. Process for preparation of troxerutin from rutin. China, CN106589017B, 2019-10-29.
- [6] Luo JW, Zhao XX, Li C. Dimeflin hydrochloride intermediate 7-methoxy-3-methylflavone preparation method and its application. China, CN112625019A, 2021-04-09.
- [7] Ok Jang D, Hyan Cho D, Kim JG. One-pot preparation of esters from carboxylic acids using the PPh<sub>3</sub>-CCl<sub>3</sub>CN System. *Synthetic communications*, 2003, 33(16): 2885-2890.
- [8] Weiss M, Miskin H, Sportelli P, et al. Combination of anti-cd20 antibody and pi3 kinase selective inhibitor. WO2014071125 A1, 2014-5-8.
- [9] Satya VSKV, Meyyappan M, Dhanapalan N. Preparation of 1*H*-pyrazolo[3,4-*d*]pyrimidine derivatives as selective PI3K delta inhibitors for treatment of autoimmune and inflammatory disorders, and proliferative diseases. World Intellectual Property Organization, WO2014006572A1, 2014-01-09.
- [10] Liu H, Tang JG. An improved synthesis process of Ipriflavone. *Chemical Production and Technology*, 2009, 16(1): 18-20.
- [11] Wang JG, Wu L, Tao CY, et al. One-pot process for preparation of Sofalcone from 2', 4',4'-trihydroxychalcone. China, CN101698641A, 2010-04-28.
- [12] Ali A, Ghosh A, Nathans RS, et al. Identification of Flavopiridol analogues that selectively inhibit positive transcription elongation factor (P-TEFb) and block HIV-1 replication. *Chembiochem*, 2009, 10(12): 2072-2080.
- [13] Zhang N, Zheng BF. A process for preparing Flavopiridol. China, CN101665487A, 2010-03-10.
- [14] Steven W, Stephen A, David B, et al. Combination therapies for treatment of myelodysplastic syndrome comprising a hypomethylating agent and alvocidib. World Intellectual Property Organization, WO2021113688A1, 2021-06-10.
- [15] Joyce RM, Sanjay JK. Pharmaceutical combination of paclitaxel and cyclindependent kinase (CDK) inhibitors for treatment of breast cancer. World Intellectual Property Organization, WO2012066508A1, 2012-05-24.
- [16] Moohi Y, Won SM, Yon KI, et al. Preparation of gastro-protective flavones and flavanones for treatment of inflammatory bowel disease. World Intellectual Property Organization, WO9804541A1, 1998-02-05.
- [17] Guo ZR, Tang RY, Li XF, et al. Preparation of chromene-4-one compound and its intermediate. China, CN116444521A, 2023-07-18.
- [18] Wang X, Liu B, Searle X, et al. Discovery of 4-[(2*R*, 4*R*)-4-({[1-(2, 2-Difluoro-1,3-benzodioxol-5-yl) cyclopropyl] carbonyl} amino)-7-(difluoromethoxy)-3, 4-dihydro-2 *H*-chromen-2-yl] benzoic Acid (ABBV/GLPG-2222), a potent cystic fibrosis transmembrane conductance regulator (CFTR) corrector for the treatment of cystic fibrosis. *Journal of Medicinal Chemistry*, 2018, 61(4): 1436-1449.
- [19] Calvin JR, Frederick MO, Laird DL, et al. Rhodium-catalyzed and zinc(II)-triflate-promoted asymmetric hydrogenation of tetrasubstituted  $\alpha$ ,  $\beta$ -unsaturated ketones. *Organic Letters*, 2012, 14(4): 1038-1041.

- [20] Zhen Y, Wang GJ, Chang RR, et al. Green preparation of phenoxyacetic acid derivatives. China, CN113121394A, 2021-07-16.
- [21] Jung C, Li S, Lee K, et al. Reagent-free intramolecular hydrofunctionalization: a regioselective 6-endo-dig cyclization of *o*-alkynoylphenols. *Green Chemistry*, 2022, 24(6): 2376-2384.
- [22] Veena A, Giridharan P, Maggie R, et al. A pharmaceutical combination for the treatment of melanoma. World Intellectual Property Organization, WO2015004636A1, 2015-01-15.
- [23] Tong HJ, Liu B, Tang WQ. Synthesis process of 2-(2-amino-3-methoxyphenyl) chromone from 2-hydroxyacetophenone and 3-methoxy-2-nitrobenzoic acid. China, CN111138398A, 2020-05-12.
- [24] Akama T, Ishida H, Kimura U, et al. Structure-activity relationships of the 7-substituents of 5,4'-diamino-6,8,3'-trifluoroflavone, a potent antitumor agent. *Journal of Medicinal Chemistry*, 1998, 41(12): 2056-2067.
- [25] Wu ES, Cole TE, Davidson TA, et al. Flavones. 2. Synthesis and structure-activity relationship of flavodilol and its analogues, a novel class of antihypertensive agents with catecholamine depleting properties. *Journal of Medicinal Chemistry*, 1989, 32(1): 183-192.
- [26] Giancarlo S, Aeri K, Michael LF, et al. Preparation and formulation of 8-[(piperazinopropyl)carbamoyl]-4-oxobenzopyrans and analogs as  $\alpha$ -adrenoceptor antagonists. World Intellectual Property Organization, WO9714419A1, 1997-04-24.
- [27] Dante N, Alberto T, Pietro C, et al. 3-Methylflavone-8-carboxylic acid esters. European Patent Organization, EP72620A1, 1983-02-23.
- [28] Erickson RH, Natalie KJJr, Bock W, et al. (Aminoalkoxy)chromones. Selective sigma receptor ligands. *Journal of Medicinal Chemistry*, 1992, 35(9): 1526-1535.
- [29] Shi L, Feng XE, Cui JR, et al. Synthesis and biological activity of flavanone derivatives. *Bioorganic & Medicinal Chemistry Letters*, 2010, 20(18): 5466-5468.
- [30] Yuan CJ, Chen S, Luo S, et al. Preparation of isoflavone derivative for treating Cocksackie virus. China, CN106554339B, 2019-03-08.
- [31] Yuan CJ, Chen S, Luo S, et al. Preparation and purification of tectorigenin sodium sulfonate. China, CN110396077B, 2021-02-12.
- [32] Oslund RC, Cermak N, Verlinde CL, et al. Simplified YM-26734 inhibitors of secreted phospholipase A2 group IIA. *Bioorganic & Medicinal Chemistry Letters*, 2008, 18(20): 5415-5419.
- [33] Sadakazu Y, Keiko S, Tohru M, et al. Preparation of chalcone derivatives as antiulcer agents. European Patent Organization, EP412803A1 1991-02-13.



**Figure S1.** Bioinformatic analysis for flavonoid-based marketed drugs (1–4 and 6–19) and clinical candidates (20–51 and 53–55). (A) Sankey diagram of drug-target-pathway. (B) Bar graph of GO pathway annotation analysis. (C) Bar plot of KEGG pathway annotation analysis.



**Table S1.** The original structural and physicochemical parameters of flavonoid-based drugs (1–4 and 6–19) and candidates (20–51 and 53–55).

NO.	CAS	SMILLES	MW	H-Donors	H-Acceptors	cLog P	cLog S	Rotatable Bonds	Polar Surface Area	sp3-Atoms	total C	sp3/total C	Aromatic Rings	Total Surface Area	Relative PSA	Stereo Centers	nStereo/MW	Small Rings	Hetero-Rings	Hetero-Rings/Rings	RngA r/Rings	Shape Index	Molecular Flexibility	Molecular Complexity
1	22368-21-4	<chem>COC1=CC(C(OC2=CC(O)=C(C(O)=C23)OC)=CC3=O)=CC=C1OC</chem>	344.32	2	7	2.47	-3.21	4	94.45	9	18	0.5000	2	251.46	0.31512	0	0.0000	3	1	0.33	0.67	0.56	0.29	0.88
2	520-27-4	<chem>O[C@H]([C@H]1O)[C@@H](O[C@@H](OC[C@H](O[C@H]2OC3=CC(OC(C4=CC=C(C(O)=C4)OC)=CC5=O)=C5C(O)=C3)[C@H]([C@H]([C@H]2O)O)[C@H]1O)C</chem>	608.55	8	15	-0.63	-2.97	7	234.29	27	28	0.9643	2	409.06	0.43475	10	0.0164	5	3	0.60	0.40	0.51	0.35	0.95
3	119-41-5	<chem>O=C(OC)COC1=CC=C2C(C=C(C3=CC=CC=C3)OC2=C1)=O</chem>	324.33	0	5	3.27	-3.97	6	61.83	6	19	0.3158	2	249.51	0.22476	0	0.0000	3	1	0.33	0.67	0.63	0.35	0.80
4	21967-41-9	<chem>OC1=C(C2=O)C(OC(C3=CC=CC=C3)=C2)=CC(O[C@H]4[C@H](O)[C@H]([C@H]([C@H](O4)C)=O)O)=C1O</chem>	446.36	6	11	0.00	-2.72	4	183.21	14	21	0.6667	2	296.83	0.45373	5	0.0112	4	2	0.50	0.50	0.47	0.20	0.93
6	27740-01-8	<chem>O[C@H]1[C@@H](O[C@H](C(O)=O)[C@@H](O)[C@@H]1O)OC2=CC(OC(C3=CC=C(C=C3)O)=CC4=O)=C4C(O)=C2O</chem>	462.36	7	12	-0.35	-2.43	4	203.44	15	21	0.7143	2	303.18	0.48743	5	0.0108	4	2	0.50	0.50	0.48	0.20	0.93
7	13358-62-8	<chem>O=C(COC1=C2C(OC(C3=CC=CC=C3)=CC2=O)=CC(OCC(O[Na])=O)=C1)O[Na]</chem>	414.28	0	8	-2.66	-3.33	7	125.02	7	19	0.3684	2	261.5	0.3408	0	0.0000	3	1	0.33	0.67	0.48	0.35	0.87
8	7085-55-4	<chem>O=C1C(O[C@@H]([C@@H]([C@@H](O)[C@@H]2O)O)[C@@H]2CO[C@H](O)[C@@H](C)[C@H](O)[C@H]3O)[C@@H]3O)=C(C4=CC(OCCO)=C(OCCO)C=C4)OC5=CC(OCCO)=CC(O)=C15</chem>	742.68	10	19	-1.99	-2.72	15	293.21	36	33	1.0909	2	510.27	0.43906	10	0.0135	5	3	0.60	0.40	0.40	0.41	0.99
9	118525-40-9	<chem>OC1=C(OC2=C(C(O)=CC(O)=C2C1=O)C/C=C(C)C)C3=CC=C(C=C3)OC</chem>	368.38	3	6	4.13	-4.04	4	96.22	9	21	0.4286	2	274.49	0.26354	0	0.0000	3	1	0.33	0.67	0.52	0.35	0.91
10	2740/47	<chem>O=C1C2=C(OC(C3=CC=CC=C3)=C1C)C(C[N+](C)(H)C)=C(OC)C=C2.[Cl-]</chem>	323.39	0	4	3.37	-3.40	4	38.77	8	24	0.3333	2	253.29	0.14446	0	0.0000	3	1	0.33	0.67	0.46	0.33	0.89
11	15301-69-6	<chem>O=C1C2=C(OC(C3=CC=CC=C3)=C1C)C(C(OCN4CCCC4)=O)=CC=C2</chem>	391.47	0	5	4.56	-4.39	6	55.84	11	20	0.5500	2	303.32	0.16362	0	0.0000	4	2	0.50	0.50	0.55	0.38	0.88
12	520-26-3	<chem>O=C1C(C(O)=CC(O[C@@H]2O[C@H](CO)[C@H]3[C@H](O)[C@H](O)[C@@H](CO3)[C@@H](O)[C@H](O)[C@H]2O)=C4=C4O[C@H](C5=CC=C(OC)C(O)=C5)C1</chem>	610.56	8	15	-0.81	-2.75	7	234.29	29	28	1.0357	2	410.61	0.43311	11	0.0180	5	3	0.60	0.40	0.51	0.35	0.95
13	22888-70-6	<chem>O=C1[C@H](O)[C@@H](C2=CC=C(O)[C@H](CO)[C@H](C3=CC=C(C(O)C(OC)=C3)O4)C4=C2)OC5=C(C(O)=CC(O)=C15</chem>	482.44	5	10	2.13	-3.41	4	155.14	15	25	0.6000	3	331.3	0.3578	4	0.0083	5	2	0.40	0.60	0.46	0.32	0.94
14	153253-3-67-7	<chem>NC(N=CN=C12)=C2C(C3=CC=C(C(F)=C3)OC(C)O)=NN1[C@H](C)C(OC4=CC=C(C=C4C5=O)F)=C5C6=CC=CC(F)=C6</chem>	571.56	1	8	5.28	-8.55	6	105.15	7	31	0.2258	5	409.14	0.21531	1	0.0017	6	3	0.50	0.83	0.43	0.31	1.00
15	3681-99-0	<chem>OC1=CC=C2C(OC=C(C3=CC=C(O)C=C3)C2=O)=C1[C@H]([C@@H]([C@H](O)[C@@H]4O)O)[C@H]4CO</chem>	416.38	6	9	-0.44	-2.44	3	156.91	14	21	0.6667	2	282.84	0.39471	5	0.0120	4	2	0.50	0.50	0.50	0.33	0.95

16	35212-22-7	CC(C)OC1=CC=C(C2=O)C(OC=C2C3=CC=CC=C3)=C1	280.32	0	3	3.36	-4.31	3	35.53	5	18	0.2778	2	219	0.15087	0	0.0000	3	1	0.33	0.67	0.62	0.33	0.79
17	486-66-8	OC1=CC=C(C2=O)C(OC=C2C3=C=C(C=C3)O)=C1	254.24	2	4	1.97	-3.02	1	66.76	3	15	0.2000	2	184.68	0.26662	0	0.0000	3	1	0.33	0.67	0.63	0.30	0.78
18	154-23-4	O[C@@H]1[C@@H](C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C3C1	290.27	5	6	1.51	-1.76	1	110.38	9	15	0.6000	2	200.03	0.37744	2	0.0069	3	1	0.33	0.67	0.52	0.28	0.82
19	64506-49-6	O=C(O)COC1=CC(OC/C=C(C)C)=CC=C1C/C=C/C2=CC=C(OC/C=C(C)C)C=C2=O	450.53	1	6	5.56	-5.14	12	82.06	11	27	0.4074	2	371.11	0.18641	0	0.0000	2	0	0.00	1.00	0.64	0.52	0.77
20	491-67-8	O=C1C=C(C2=CC=CC=C2)OC3=C(C(O)=C(O)C(O)=C13	270.24	3	5	2.34	-2.86	1	86.99	4	15	0.2667	2	191.03	0.32634	0	0.0000	3	1	0.33	0.67	0.55	0.23	0.83
21	632-85-9	O=C1C=C(C2=CC=CC=C2)OC3=C(OC)C(O)=CC(O)=C13	284.27	2	5	2.61	-3.17	2	75.99	5	16	0.3125	2	206.94	0.28627	0	0.0000	3	1	0.33	0.67	0.48	0.27	0.86
22	146426-40-6	C1C1=CC=CC=C1C(OC2=C(C(O)=CC(O)=C23)C@H](C@H)(C4O)CCN4C)=CC3=O	401.85	3	6	3.52	-3.87	2	90.23	11	21	0.5238	2	281.79	0.23383	2	0.0050	4	2	0.50	0.50	0.46	0.27	0.93
23	204468-6-42-0	O=C1C=C(C2=CC=CC=C2)OC3=C(C1C@H)4C@H(C@H)(O)CN(C)CC4)C(OP(O)(O)=O)=CC(O)=C13	481.82	4	9	-0.65	-2.76	4	146.57	14	21	0.6667	2	321.91	0.32932	2	0.0042	4	2	0.50	0.50	0.41	0.33	0.95
24	1000023-04-0	C1C1=CC(C(F)(F)F)=CC=C1C(OC2=C(C(O)=CC(O)=C23)C@H](C@H)(C4O)CCN4C)=CC3=O	469.84	3	6	4.27	-4.65	4	90.23	12	22	0.5455	2	311.25	0.21169	2	0.0043	4	2	0.50	0.50	0.44	0.33	0.95
25	203191-10-0	COC1=CC(C(OC2=CC(O)C(O)=O)=CC(O)C23)=CC3=O)=CC=C1O	386.36	1	8	2.22	-3.59	7	100.52	10	20	0.5000	2	286.62	0.31114	0	0.0000	3	1	0.33	0.67	0.54	0.32	0.86
26	480-11-5	OC1=C2C(OC(C3=CC=CC=C3)=C2=O)=CC(O)=C1OC	284.27	2	5	2.61	-3.17	2	75.99	5	16	0.3125	2	206.94	0.28627	0	0.0000	3	1	0.33	0.67	0.57	0.27	0.85
27	528-48-3	OC1=CC(C(OC2=CC(O)=CC=C2C3=O)=C3O)=CC=C1O	286.24	4	6	1.84	-2.79	1	107.22	5	15	0.3333	2	195.59	0.3857	0	0.0000	3	1	0.33	0.67	0.52	0.30	0.84
28	117-39-5	OC1=CC(C(OC2=CC(O)=CC(O)=C2C3=O)=C3O)=CC=C1O	302.24	5	7	1.49	-2.49	1	127.45	6	15	0.4000	2	201.94	0.43845	0	0.0000	3	1	0.33	0.67	0.50	0.29	0.85
29	482-35-9	OC(C=CC(C1=C(O)C@H)2[C@H](O)C@H)(C@H)(C@H)(O2CO)O)C(C3=C(O)C=C(C=C3O1)O)=O=C4=C4O	464.38	8	12	-0.35	-2.19	4	206.6	17	21	0.8095	2	303.75	0.48672	5	0.0108	4	2	0.50	0.50	0.39	0.36	0.94
30	480-39-7	O=C1C[C@@H](C2=CC=CC=C2)OC3=CC(O)=CC(O)=C13	256.26	2	4	2.50	-2.94	1	66.76	5	15	0.3333	2	186.23	0.2644	1	0.0039	3	1	0.33	0.67	0.53	0.25	0.79
31	93602-28-9	O=C1CC(C2=CC=C(O)C=C2)OC3=C1C(O)=CC(O)=C3	272.26	3	5	2.16	-2.64	1	86.99	6	15	0.4000	2	192.58	0.32371	1	0.0037	3	1	0.33	0.67	0.55	0.25	0.80
32	10236-47-2	O[C@H](C@H)(C@H)1O[C@@H](O)C@@H(O)C@@H)2[C@H](C@H)(C@H)(O)C@H)2OC3=CC4=C(C(C(C@H)1O4)C5=CC=C(C=C5)O)=O)C(O)=C3CO)O)C@H)1O	580.54	8	14	-0.74	-2.73	6	225.06	27	27	1.0000	2	388.35	0.43219	11	0.0189	5	3	0.60	0.40	0.46	0.30	0.96
33	1639417-53-0	FC1=CC(C2=C(OC3=CC=CC=C3C2=O)C@H)(CC)NC4=C5C(NC=N5)=NC=N4)=CC=C1	415.43	2	7	3.65	-6.40	5	92.79	4	23	0.1739	4	306.73	0.26538	1	0.0024	5	3	0.60	0.80	0.39	0.30	0.95
34	446-72-0	OC1=C(C2=O)C(OC=C2C3=CC=C(C=C3)O)=CC(O)=C1	270.24	3	5	1.63	-2.73	1	86.99	4	15	0.2667	2	191.03	0.32634	0	0.0000	3	1	0.33	0.67	0.60	0.29	0.80
35	490-46-0	OC1=CC(C@H)2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C1O	290.27	5	6	1.51	-1.76	1	110.38	9	15	0.6000	2	200.03	0.37744	2	0.0069	3	1	0.33	0.67	0.52	0.30	0.82
36	989-51-5	O=C(O)C@H)1[C@@H](C2=CC(O)=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C3C1)C4=CC(O)=C(O)C(O)=C4	458.37	8	11	2.05	-2.16	4	197.37	13	22	0.5909	3	306.59	0.44959	2	0.0044	4	1	0.25	0.75	0.42	0.29	0.87
37	1918143-53-9	FC1(OC2=CC(C3CC3)C(N)C@H)(C4)C5=CC=C(C=C5O)C@H)4C6=CC=C(C(O)=O)C=C6OC(F)F)=CC=C2O1)F	559.47	2	8	6.02	-6.40	7	103.32	13	28	0.4643	3	370.59	0.24458	2	0.0036	6	2	0.33	0.50	0.45	0.36	0.92

